Although patients with high PD‐L1 expression have been mainly treated with pembrolizumab monotherapy in our institution, those with a high tumour burden were treated with PD‐1/PD‐L1 inhibitors plus chemotherapy. This evidence concerns the gene CD274 and neoplasm.